Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 7/20 | 0.58 |
| ▸ | CYP1B1 | Q16678 | 7/20 | 0.58 |
| ▸ | P4HB | P07237 | 1/20 | 0.58 |
| ▸ | MAOB | P27338 | 9/20 | 0.56 |
| ▸ | MAOA | P21397 | 4/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.48 |
| ▸ | STAT3 | P40763 | 1/20 | 0.47 |
| ▸ | GPR183 | P32249 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3746445 | 0.93 | CYP1A1 (0.58) | CYP1A1CYP1B1P4HBMAOBCXCL12 | |
| SCHEMBL3740803 | 0.81 | MAOB (0.74) | CYP1A1CYP1B1P4HBMAOBMAOA | |
| SCHEMBL11816718 | 0.79 | CYP1A1 (0.87) | CYP1A1CYP1B1P4HBMAOBMAOA | |
| SCHEMBL11816722 | 0.79 | CYP1A1 (0.87) | CYP1A1CYP1B1P4HBMAOBMAOA | |
| Bromide SCHEMBL11817515 | 0.78 | CYP1A1 (0.84) | CYP1A1CYP1B1P4HBMAOBMAOA | |
| Hydrochloric Acid SCHEMBL11819369 | 0.78 | CYP1A1 (0.84) | CYP1A1CYP1B1P4HBMAOBMAOA | |
| Hydrochloric Acid SCHEMBL11819375 | 0.78 | CYP1A1 (0.84) | CYP1A1CYP1B1P4HBMAOBMAOA | |
| Bromide SCHEMBL11817521 | 0.78 | CYP1A1 (0.84) | CYP1A1CYP1B1P4HBMAOBMAOA | |
| SCHEMBL2665097 | 0.77 | CYP2D6 (0.48) | CYP1A1CYP1B1MAOBMAOASTAT3 | |
| SCHEMBL7062928 | 0.77 | CYP2D6 (0.48) | CYP1A1CYP1B1MAOBMAOASTAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7829563-B2 | Aminoamides as orexin antagonists | HOFFMANN-LA ROCHE INC. (US) | 2010-11-09 | — | — | US | disclosed |
| EP-2114867-A1 | AMINOAMIDES AS OREXIN ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008107335-A1 | AMINOAMIDES AS OREXIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-09-12 | — | — | WO | disclosed |
| US-20080221166-A1 | AMINOAMIDES AS OREXIN ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221166-A1 | AMINOAMIDES AS OREXIN ANTAGONISTS | HCRTR1, HCRTR2, HRH3 | CYP1A1 1184/4885CYP1B1 976/4885P4HB 4731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.